Cargando…
Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1
Lung adenocarcinoma is the major subtype of lung cancer, accounting for approximately 40% of lung cancers. During clinical treatment, the emergence of chemotherapy resistance seriously affects the effectiveness of treatment. Thus, finding new chemotherapeutic sensitizers is considered to be one of t...
Autores principales: | Li, Jianjun, Kou, Yaqi, Zhang, Xiaohan, Xiao, Xuechun, Ou, Yang, Cao, Lixia, Guo, Min, Qi, Chunchun, Wang, Zhaoyang, Liu, Yuxin, Shuai, Qiuying, Wang, Hang, Yang, Shuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748019/ https://www.ncbi.nlm.nih.gov/pubmed/36512117 http://dx.doi.org/10.1007/s12672-022-00601-2 |
Ejemplares similares
-
USP51/PD‐L1/ITGB1‐deployed juxtacrine interaction plays a cell‐intrinsic role in promoting chemoresistant phenotypes in non‐small cell lung cancer
por: Li, Jianjun, et al.
Publicado: (2023) -
Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer
por: Jiang, Huimin, et al.
Publicado: (2022) -
Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer
por: Xu, Junying, et al.
Publicado: (2022) -
CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism
por: Zhang, Zhen, et al.
Publicado: (2020) -
Correction to: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism
por: Zhang, Zhen, et al.
Publicado: (2020)